What are the contraindications for daprodustat?

Contraindications of Daprodustat

Based on FDA labeling and clinical evidence, daprodustat has no absolute contraindications explicitly stated in the available evidence, though specific populations should avoid this medication based on safety concerns and lack of data.

Populations That Should NOT Receive Daprodustat

Explicitly Excluded from Trials and Approval:

• Patients NOT on dialysis - The FDA approved daprodustat only for patients already receiving dialysis for at least 4 months, NOT for non-dialysis CKD patients 1
• Pediatric patients under 18 years - All phase 3 trials excluded patients under age 18, with insufficient safety data in children 2
• Patients with polycystic kidney disease - HIF activation enhances cyst expansion in preclinical models; these agents should not be used until adequate safety data emerge 2
• Kidney transplant recipients - Transplant patients were excluded from trials, and HIF-PHIs may promote graft rejection or increase malignancy risk due to immunosuppression interactions 2

Strong Clinical Cautions (Avoid Use):

• Active or recent malignancy - In the ASCEND-ND trial, cancer-related death or tumor progression occurred more frequently with daprodustat (3.7%) versus darbepoetin alfa (2.5%), with relative risk 1.47 (95% CI: 1.03–2.10) 2. Post-marketing surveillance is critical, and avoidance in patients with history of malignancy is recommended 2

• Pregnancy and lactation - No adequate controlled studies exist in pregnant women; use only if clearly needed. Unknown if excreted in breast milk 3

Key Safety Considerations

Drug-Drug Interactions Requiring Caution:

Daprodustat undergoes significant DDIs through OATP1B and CYP2C8 pathways 4:

• Strong CYP2C8 and/or OATP1B inhibitors (gemfibrozil, clopidogrel, rifampin, cyclosporine) cause moderate-to-strong interactions with up to 18-fold increase in daprodustat AUC 4
• These combinations may require dose adjustment or avoidance

Monitoring Requirements:

While not contraindications, the following warrant heightened vigilance:

• Thromboembolism risk - Though daprodustat trials showed no excess thrombosis versus ESAs 2, thrombotic events remain a concern with HIF-PHIs as a class
• Cardiovascular disease - MACE rates were similar to ESAs in trials 2, 1, but careful monitoring remains essential
• Hepatic dysfunction - PK modeling shows altered drug exposure in hepatic impairment 4

Clinical Algorithm for Daprodustat Use

Proceed with daprodustat ONLY if:

1. Patient is on dialysis ≥4 months
2. Age ≥18 years
3. No active/recent malignancy
4. Not pregnant or breastfeeding
5. No polycystic kidney disease
6. No kidney transplant
7. Review all medications for CYP2C8/OATP1B inhibitors

If any of the above criteria are not met, use alternative anemia therapy (ESAs or other HIF-PHIs with broader approval).

Common Pitfall to Avoid:

The most critical error is prescribing daprodustat to non-dialysis CKD patients, as FDA approval is restricted to dialysis patients only despite efficacy shown in non-dialysis populations in trials 1.